Chinese Journal of Antituberculosis ›› 2019, Vol. 41 ›› Issue (6): 700-704.doi: 10.3969/j.issn.1000-6621.2019.06.020
• Review Articles • Previous Articles Next Articles
Received:
2019-02-11
Online:
2019-06-10
Published:
2019-06-04
Contact:
Yu LU
E-mail:luyu4876@hotmail.com
Jiao-jie ZHAO,Yu LU. Research and progress of PK/PD for anti-tuberculosis drugs[J]. Chinese Journal of Antituberculosis, 2019, 41(6): 700-704. doi: 10.3969/j.issn.1000-6621.2019.06.020
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2019.06.020
[1] | World Health Organization . Global tuberculosis report 2018. Geneva:World Health Organization, 2018. |
[2] |
Knazek RA, Gullino PM, Kohler PO , et al. Cell culture on artificial capillaries: an approach to tissue growth in vitro. Science, 1972,178(4056):65-66.
doi: 10.1126/science.178.4056.65 URL |
[3] | Shah PM . An improved method to study antibacterial activity of antibiotics in an vitromodel simulating serum levels. Methods Find Exp Clin Pharmacol, 1980,2(4):171-176. |
[4] |
Cavaleri M, Manolis E . Hollow fiber system model for tuberculosis: The European medicines agency experience. Clin Infect Dis, 2015, 61 Suppl 1: S1-4.
doi: 10.1093/cid/civ484 URL |
[5] | 李媛媛, 陆宇 . 动物模型在抗结核新药药效学评价中的应用. 中国防痨杂志, 2017,39(9):1014-1017. |
[6] |
Timmins GS, Deretic V . Mechanisms of action of isoniazid. Mol Microbiol, 2006,62(5):1220-1227.
doi: 10.1111/mmi.2006.62.issue-5 URL |
[7] | 郎美琦, 蒋利, 黄佳盛 . 抗结核病药物治疗综述. 临床肺科杂志, 2010,15(8):1153-1154. |
[8] |
Gumbo T, Louie A, Liu W , et al. Isoniazid’s bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis, 2007,195(2):194-201.
doi: 10.1086/521712 URL |
[9] |
Gumbo T . New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother, 2010,54(4):1484-1491.
doi: 10.1128/AAC.01474-09 URL |
[10] |
Almeida Da Silva PE, Palomino JC . Molecular basis and mecha-nisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother, 2011,66(7):1417-1430.
doi: 10.1093/jac/dkr173 URL |
[11] |
Gumbo T, Louie A, Deziel MR , et al. Concentration-depen-dent Mycobacterium tuberculosis killing and prevention of resis-tance by rifampin. Antimicrob Agents Chemother, 2007,51(11):3781-3788.
doi: 10.1128/AAC.01533-06 URL |
[12] |
Sirgel FA, Fourie PB, Donald PR , et al. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med, 2005,172(1):128-135.
doi: 10.1164/rccm.200411-1557OC URL |
[13] |
Diacon AH, Patientia RF, Venter A , et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother, 2007,51(8):2994-2996.
doi: 10.1128/AAC.01474-06 URL |
[14] |
Gumbo T, Dona CS, Meek C , et al. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother, 2009,53(8):3197-3204.
doi: 10.1128/AAC.01681-08 URL |
[15] | Alsultan A, Savic R, Dooley KE , et al. Population pharmacokinetics of pyrazinamide in patients with tuberculosis. Antimicrob Agents Chemother, 2017, 61(6). pii:e02625-16. |
[16] |
Takayama K, Kilburn JO . Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother, 1989,33(9):1493-1499.
doi: 10.1128/AAC.33.9.1493 URL |
[17] |
Lakshminarayana SB, Huat TB, Ho PC , et al. Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents. J Antimicrob Chemother, 2015,70(3):857-867.
doi: 10.1093/jac/dku457 URL |
[18] |
Srivastava S, Musuka S, Sherman C , et al. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis, 2010,201(8):1225-1231.
doi: 10.1086/651174 URL |
[19] | Van’t Boveneind-Vrubleuskaya N, Seuruk T, van Hateren K , et al. Pharmacokinetics of levofloxacin in multidrug-and extensively drug-resistant tuberculosis patients. Antimicrob Agents Chemother, 2017, 61(8). pii:e00343-17. |
[20] |
Zhou CC, Swaney SM, Shinabarger DL , et al. 1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes. Antimicrob Agents Chemother, 2002,46(3):625-629.
doi: 10.1128/AAC.46.3.625-629.2002 URL |
[21] |
Leach KL, Swaney SM, Colca JR , et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell, 2007,26(3):393-402.
doi: 10.1016/j.molcel.2007.04.005 URL |
[22] |
Tsona A, Metallidis S, Foroglou N , et al. Linezolid penetration into cerebrospinal fluid and brain tissue. J Chemother, 2010,22(1):17-19.
doi: 10.1179/joc.2010.22.1.17 URL |
[23] |
Alsultan A, Peloquin CA . Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs, 2014,74(8):839-854.
doi: 10.1007/s40265-014-0222-8 URL |
[24] | Brown AN, Drusano GL, Adams JR , et al. Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy. MBio, 2015,6(6):e01741-15. |
[25] |
Bolhuis MS, Akkerman OW, Sturkenboom MGG , et al. Line-zolid-based regimens for multidrug-resistant tuberculosis (TB): A systematic review to establish or revise the current recommended dose for TB treatment. Clin Infect Dis, 2018,67 Suppl 3: S327-335.
doi: 10.1093/cid/ciy625 URL |
[26] |
Andries K, Verhasselt P, Guillemont J , et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005,307(5707):223-227.
doi: 10.1126/science.1106753 URL |
[27] | 应苗法, 朱剑萍, 马珂 , 等. 新型抗结核药物贝达喹啉的作用及其研究进展. 中国新药与临床杂志, 2014,33(5):325-329. |
[28] |
Matsumoto M, Hashizume H, Tomishige T , et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med, 2006,3(11):e466.
doi: 10.1371/journal.pmed.0030466 URL |
[29] |
Gupta R, Wells CD, Hittel N , et al. Delamanid in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2016,20(12):33-37.
doi: 10.5588/ijtld.16.0125 URL |
[30] |
Gler MT, Skripconoka V, Sanchez-Garavito E , et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med, 2012,366(23):2151-2160.
doi: 10.1056/NEJMoa1112433 URL |
[1] | MA Ting-long, HAN Yi, CHENG Xu, LIU Zhi-dong. Clinical observation on treatment effectiveness of transdermal ultrasound-mediated drug delivery combined with oral anti-tuberculosis drug in patients with chest wall tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 968-972. |
[2] | LI Ai-fang, CUI Xiao-li, KANG Lei, LEI Jing, DANG Li-yun, YANG Han. Value of fluorescence PCR probe melting curve method in detecting resistance of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 998-1001. |
[3] | Beijing Chest Hospital, Capital Medical University, Non-tuberculous Mycobacterial Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus on off-label use of drugs for non-tuberculous mycobacteria [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 769-787. |
[4] | YANG Lei, WEI Fen, ZHANG Kai, QIU Jing-jing, WANG Ying-ying, DU Wei-xin, LU Jin-biao, TAO Li-feng, PU Jiang. Stability and efficacy study of recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 799-806. |
[5] | ZHANG Kai, TAO Li-feng, WEI Fen, DU Wei-xin, QIU Jing-jing, CHEN Wei, CHEN Bao-wen, ZHU Yin-meng, CHENG Xing, SU Cheng, ZHONG Zai-xin, LU Jin-biao, PU Jiang. Immune characteristics and preclinical animal safety studies of recombinant Mycobacterium tuberculosis fusion protein(EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 807-813. |
[6] | ZHANG Kai, SHEN Xiao-bing, TAO Li-feng, WEI Fen, CHEN Bao-wen, QIU Jing-jing, CHEN Wei, LU Jin-biao, ZHU Yin-meng, CHENG Xing, ZHONG Zai-xin, ZHAO Ai-Hua, PU Jiang. Establishment of quality standards for recombinant Mycobacterium tuberculosis fusion protein [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 814-820. |
[7] | SHENG Jie, ZHU Yang, Dilixiati·Abulizi , TANG Wei, GU Fu-ding, SONG Xing-hua. Individualized treatment of drug-resistant osteoarticular tuberculosis based on phenotypic and molecular drug susceptibility tests and its short-term effectiveness evaluation [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 838-844. |
[8] | YANG Lu-qi, SHEN Ming-yi, SHA Wei, CHEN Ying-ying, WANG Ying. Research progress in immunoprotective mechanism of bacille Calmette-Guérin and vaccine development strategies [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 863-868. |
[9] | WANG Ni, ZHANG Hui, ZHANG Tie-juan, CHEN Bin, LEI Juan, SUN Miao-miao, HUANG Fei. Analysis of using electronic pillbox to assist the medication management of pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 682-686. |
[10] | XIE Li, GAO Jing-tao, MA Li-ping, ZHANG Li-qun, KONG Zhong-shun, WU Xiao-guang, LIU Rong-mei, CHEN Hong-mei, SONG Yan-hua, LI Xue-lian, Huang Mai-ling, LI Qiang, Lv Zi-zheng, LIu Yv-hong, Gao Meng-qiu. Effect of bedaquiline-containing regimen on QT interval in patients with multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 687-694. |
[11] | BAO Xun-di, JIANG Yue, LIANG Suo, CHENG Hong-yan, XIA Guang-xiu, WANG Chao, YE Qian, WANG Shu, WANG Qing. Analysis of the clinical isolation rate, population distribution and drug resistance of non-tuberculous mycobacteria in Anhui [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 718-724. |
[12] | Beijing Chest Hospital, Capital Medical University, Clinical Trial Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Guideline for clinical application of cycloserine in the treatment of tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 533-540. |
[13] | XU Yan, LU Xi-wei, CAI Chun-kui, SUN Shi-xue, GU Xiao-feng, YU Yang, LI Gang, WANG Ying. Retrospective study of CT imaging evolution of treatment failure patients with multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 549-557. |
[14] | ZHANG Pei-ze, FU Liang, TAN Jie, WANG Yu-xiang, CHEN Tao, DENG Guo-fang. CT imaging characteristics of cured multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 558-562. |
[15] | LIANG Xiao-yan, LIN Mei, LIANG Da-bin, LAN Ru-shu, QIN Hui-fang, YE Jing, HUANG Li-wen. Drug resistance and genotypic characteristics of multidrug-resistant Mycobacterium tuberculosis in Guangxi Zhuang Autonomous Region [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 578-582. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||